Comparison of the efficacy and safety of platelet-rich-plasma and autologous-serum eye drops in primary Sjögren syndrome dry eyes

Phase IV expolaratory study in comparison of efficacy, safety and usability between autologous serum and platelet rich plasma eye drops at 8 weeks after treatment in moderate to severe dry eye syndrome including Sjogren's syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0008103

Enrollment

Registered

2023-01-12

Start date

2018-03-06

Completion date

Unknown

Last updated

2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The patients were separated into two groups with randomization. All patients used their allocated eye drops (AS or PRP) at a dosage of one drop per eye six times daily in both eyes with an int

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Moderate to severe dry eye who diagnosed as Sjogren syndrome

Exclusion criteria

Exclusion criteria: patients who had other systemic diseases, who had received other eye drops, systemic steroid or immunosuppressive treatment within the previous three months, who had undergone ocular surgery within the previous three months

Design outcomes

Primary

Measure	Time frame
Corneal and conjunctival staining scores	—

Secondary

Measure	Time frame
Corneal and conjunctival staining scores;Schirmer I value ;Tear break up time;Ocular Surface Disease Index;Conjunctival impression cytology metaplasia and goblet-cell density	—

Countries

Korea, Republic of

Contacts

Public ContactMin-Ji Kang

The Catholic University of Korea, Seoul St. Mary's Hospital

mjk@paik.ac.kr+82-2-950-1101

Outcome results